Influenza virus neuraminidase inhibitors: clinical aspects

被引：4

作者：

Hayden, FG ^{[1
]}

机构：

[1] Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22901 USA

来源：

OPTIONS FOR THE CONTROL OF INFLUENZA IV | 2001年 / 1219卷

关键词：

zanamivir; oseltamivir; treatment; prophylaxis; antiviral;

D O I：

10.1016/S0531-5131(01)00358-2

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

[No abstract available]

引用

页码：797 / 806

页数：10

共 46 条

[1] Oseltamivir [J].

Bardsley-Elliot, A ;

Noble, S .

DRUGS, 1999, 58 (05) :851-860

[2] Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies [J].

Barnett, JM ;

Cadman, A ;

Gor, D ;

Dempsey, M ;

Walters, M ;

Candlin, A ;

Tisdale, M ;

Morley, PJ ;

Owens, IJ ;

Fenton, RJ ;

Lewis, AP ;

Claas, ECJ ;

Rimmelzwaan, GF ;

De Groot, R ;

Osterhaus, ADME .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :78-87

[3] Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults [J].

Boivin, G ;

Goyette, N ;

Hardy, I ;

Aoki, F ;

Wagner, A ;

Trottier, S .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1471-1474

[4] Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection [J].

Calfee, DP ;

Peng, AW ;

Cass, LM ;

Lobo, M ;

Hayden, FG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1616-1620

[5] Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir [J].

Cass, LMR ;

Gunawardena, KA ;

Macmahon, MM ;

Bye, A .

RESPIRATORY MEDICINE, 2000, 94 (02) :166-173

[6] Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers [J].

Cass, LMR ;

Brown, J ;

Pickford, M ;

Fayinka, S ;

Newman, SP ;

Johansson, CJ ;

Bye, A .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :21-31

[7]

Cassandras CG, 1999, APPL COMPUT CONT SIG, V1, P1

[8] The low potential for drug interactions with zanamivir [J].

Daniel, MJ ;

Barnett, JM ;

Pearson, BA .

CLINICAL PHARMACOKINETICS, 1999, 36 (Suppl 1) :41-50

[9] Zanamivir - A review of clinical safety [J].

Freund, B ;

Gravenstein, S ;

Elliott, M ;

Miller, I .

DRUG SAFETY, 1999, 21 (04) :267-281

[10] Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment [J].

Fritz, RS ;

Hayden, FG ;

Calfee, DP ;

Cass, LMR ;

Peng, AW ;

Alvord, WG ;

Strober, W ;

Straus, SE .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :586-593

← 1 2 3 4 5 →